JP2024520654A - ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその医療用使用 - Google Patents

３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその医療用使用 Download PDF

Info

Publication number
JP2024520654A
JP2024520654A JP2023574412A JP2023574412A JP2024520654A JP 2024520654 A JP2024520654 A JP 2024520654A JP 2023574412 A JP2023574412 A JP 2023574412A JP 2023574412 A JP2023574412 A JP 2023574412A JP 2024520654 A JP2024520654 A JP 2024520654A
Authority
JP
Japan
Prior art keywords
pharma
cycloalkyl
solvate
tautomer
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574412A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520654A5 (https=
Inventor
ボナッツィ，シモーネ
サーニジェンコ，アルチョム
ストロカ コブ，ジェニファー
デューハースト，ジャネッタ
ライアン ケリガン，ジョン
ソン，ムージュ
マリエ－フランス トムセン，ノエル
ワイエフ ティン，パメラ
オブライエン，ゲイリー
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2024520654A publication Critical patent/JP2024520654A/ja
Publication of JP2024520654A5 publication Critical patent/JP2024520654A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023574412A 2021-06-03 2022-06-01 ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその医療用使用 Pending JP2024520654A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196422P 2021-06-03 2021-06-03
US63/196,422 2021-06-03
PCT/IB2022/055131 WO2022254362A1 (en) 2021-06-03 2022-06-01 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof

Publications (2)

Publication Number Publication Date
JP2024520654A true JP2024520654A (ja) 2024-05-24
JP2024520654A5 JP2024520654A5 (https=) 2025-05-30

Family

ID=82115547

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574412A Pending JP2024520654A (ja) 2021-06-03 2022-06-01 ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその医療用使用

Country Status (22)

Country Link
US (2) US12103919B2 (https=)
EP (1) EP4347580A1 (https=)
JP (1) JP2024520654A (https=)
KR (1) KR20240013812A (https=)
CN (1) CN117062811A (https=)
AR (1) AR126052A1 (https=)
AU (1) AU2022284366A1 (https=)
BR (1) BR112023024905A2 (https=)
CA (1) CA3215410A1 (https=)
CL (1) CL2023003561A1 (https=)
CO (1) CO2024000013A2 (https=)
CR (1) CR20230614A (https=)
DO (1) DOP2023000261A (https=)
EC (1) ECSP24000004A (https=)
IL (1) IL308094A (https=)
JO (1) JOP20230308A1 (https=)
MX (1) MX2023014327A (https=)
PE (1) PE20240657A1 (https=)
PY (1) PY2243958A (https=)
TW (1) TW202306570A (https=)
UY (1) UY39796A (https=)
WO (1) WO2022254362A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122764B2 (en) * 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4612128A4 (en) 2022-11-04 2025-09-10 Bristol Myers Squibb Co COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEMOGLOBINOPATHIES
WO2025230875A1 (en) * 2024-04-29 2025-11-06 Bristol-Myers Squibb Company Compounds and their use for treatment of hemoglobinopathies
CN118598797A (zh) * 2024-05-17 2024-09-06 诚达药业股份有限公司 一种手性3-羟基-4-氟哌啶衍生物的合成方法及拆分方法
WO2026002044A1 (zh) * 2024-06-25 2026-01-02 标新生物医药科技(上海)有限公司 含有硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的双功能蛋白降解剂及它们的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543009A (ja) * 2010-11-18 2013-11-28 デューテリア ファーマシューティカルズ， インコーポレイテッド ３−ジュウテロ−ポマリドマイド
JP2020504089A (ja) * 2016-12-01 2020-02-06 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体およびテトラヒドロイソキノリン誘導体
WO2020117759A1 (en) * 2018-12-03 2020-06-11 Dana-Farber Cancer Institute, Inc. Small molecule degraders of helios and methods of use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
PL3202460T3 (pl) 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US9133161B2 (en) 2012-07-27 2015-09-15 Celgene Corporation Processes for preparing isoindoline-1,3-dione compounds
WO2017024019A1 (en) 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
EP3445765A4 (en) 2016-04-22 2019-09-18 Dana Farber Cancer Institute, Inc. DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
JP2020505327A (ja) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
KR20250117470A (ko) 2016-12-23 2025-08-04 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
BR112019015312A2 (pt) 2017-01-26 2020-03-10 Arvinas Operations, Inc. Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados
AU2018351050B2 (en) 2017-10-18 2025-09-18 Novartis Ag Compositions and methods for selective protein degradation
WO2019079701A1 (en) 2017-10-20 2019-04-25 Dana-Farber Cancer Institute, Inc. HETEROBIFUNCTIONAL COMPOUNDS HAVING IMPROVED SPECIFICITY FOR BRD4 BROMODOMAINE
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3765026A4 (en) 2018-03-10 2021-12-22 Yale University BTK PROTEOLYSIS MODULATORS AND METHODS FOR USE
WO2019195609A2 (en) 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
AU2019294835B2 (en) 2018-06-29 2025-04-17 Dana-Farber Cancer Institute, Inc. Ligands to cereblon (CRBN)
US12030892B2 (en) 2018-06-29 2024-07-09 Dana-Farber Cancer Institute, Inc. CRBN modulators
EP3814330A4 (en) 2018-06-29 2022-07-20 Dana-Farber Cancer Institute, Inc. Immunomodulatory compounds
US12060366B2 (en) 2018-06-29 2024-08-13 Dana-Farber Cancer Institute, Inc. Bispecific degraders
BR122022012697B1 (pt) * 2018-07-10 2023-04-04 Novartis Ag Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
WO2021053555A1 (en) 2019-09-16 2021-03-25 Novartis Ag Glue degraders and methods of use thereof
CA3154386A1 (en) * 2019-10-17 2021-04-22 Michael Berlin Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
PH12022551482A1 (en) 2019-12-18 2023-11-29 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543009A (ja) * 2010-11-18 2013-11-28 デューテリア ファーマシューティカルズ， インコーポレイテッド ３−ジュウテロ−ポマリドマイド
JP2020504089A (ja) * 2016-12-01 2020-02-06 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体およびテトラヒドロイソキノリン誘導体
WO2020117759A1 (en) * 2018-12-03 2020-06-11 Dana-Farber Cancer Institute, Inc. Small molecule degraders of helios and methods of use

Also Published As

Publication number Publication date
US20230019617A1 (en) 2023-01-19
WO2022254362A1 (en) 2022-12-08
BR112023024905A2 (pt) 2024-02-20
US12103919B2 (en) 2024-10-01
IL308094A (en) 2023-12-01
JOP20230308A1 (ar) 2023-11-29
ECSP24000004A (es) 2024-02-29
CA3215410A1 (en) 2022-12-08
CO2024000013A2 (es) 2024-01-25
PE20240657A1 (es) 2024-04-04
AR126052A1 (es) 2023-09-06
CN117062811A (zh) 2023-11-14
EP4347580A1 (en) 2024-04-10
AU2022284366A1 (en) 2023-10-26
CR20230614A (es) 2024-02-01
DOP2023000261A (es) 2023-12-29
MX2023014327A (es) 2023-12-13
UY39796A (es) 2023-07-31
PY2243958A (es) 2023-01-20
US20250026736A1 (en) 2025-01-23
TW202306570A (zh) 2023-02-16
KR20240013812A (ko) 2024-01-30
CL2023003561A1 (es) 2024-06-28

Similar Documents

Publication Publication Date Title
JP7682181B2 (ja) ３－（５－メトキシ－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
US12103919B2 (en) 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7659648B2 (ja) ピラゾロピリジン誘導体及びその使用
US20250276964A1 (en) Benzisoxazole Derivatives and Uses thereof
CN116802182A (zh) 吡唑并吡啶衍生物及其用途
BR112023018542B1 (pt) Derivados de pirazolopiridina, e composição e combinação farmacêuticas
EA051403B1 (ru) Производные пиразолопиридина и пути их применения
BR122025004894A2 (pt) Derivados de pirazolopiridina, seus usos, composição e combinação farmacêuticas, e kit

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250522

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224